Collegium (COLL) Reports $9.3M Net Income in Q3 2024 with Record-Breaking Product Sales
Collegium Pharmaceutical Inc. (COLL) is a trailblazer in the specialty pharmaceutical industry, dedicated to improving the lives of…
Arcutis (ARQT) Achieves $44.8M in Q3 2024 Revenue, Growing 452% Year-Over-Year
Arcutis Biotherapeutics Inc. (ARQT) is a commercial-stage biopharmaceutical company dedicated to revolutionizing the treatment of immune-mediated skin diseases.…
Amylyx (AMLX) Reports $234.4M in Cash, Secures Financial Stability Through 2026
Amylyx Pharmaceuticals Inc. (AMLX) is a cutting-edge biotechnology company dedicated to developing innovative therapies for neurodegenerative and metabolic…
MiMedx (MDXG) Reports $84M in Q3 2024 Sales, Showcasing Financial Growth
MiMedx Group Inc. (MDXG)’s a leading regenerative medicine company specializing in advanced wound care and placental tissue technologies.…
Cassava Sciences (SAVA) Secures $149M to Support Simufilam Trials Into 2026
Cassava Sciences Inc. (SAVA) is a clinical-stage biotechnology company at the forefront of advancing treatments for Alzheimer’s disease,…
Puma Biotechnology (PBYI) Reports $140.8M NERLYNX® Revenue in 2024 Amid Operational Excellence
Puma Biotechnology Inc. (PBYI) is a cutting-edge biopharmaceutical company dedicated to transforming cancer treatment through innovative therapies. Founded…
Lakeside Holding (LSH) Deepens Roots in Pharmaceutical Logistics with $1.5M Sinopharm Agreement
Lakeside Holding Limited (Nasdaq: LSH) has signed a $1.5 million sales agreement with Sinopharm Holding Hubei New Special…
NeuBase (NBSE)’s PATrOL™ Platform: The Future of RNA-Targeted Therapies
NeuBase Therapeutics Inc. (NBSE) is a biotechnology company at the forefront of genetic medicine, leveraging its proprietary PATrOL™…
Analysts Maintain Optimism as Lexicon Pharmaceuticals (LXRX) Focuses on Long-Term Growth
Lexicon Pharmaceuticals, Inc. (LXRX), founded in 1995 and headquartered in The Woodlands, Texas, is a clinical-stage biopharmaceutical company…
Mersana (MRSN) Leverages Partnerships with Johnson & Johnson (JNJ), Merck (MRK) to Advance ADCs
Mersana Therapeutics Inc. (MRSN) is a clinical-stage biopharmaceutical company leading the way in the development of novel antibody-drug…
Aditxt (ADTX)’s $32.7M Investment Fuels Growth in the $84B Autoimmune Disease Market
Aditxt Inc. (ADTX) is revolutionizing the healthcare landscape with its focus on immune system reprogramming and precision health…
Corvus (CRVS) Shows Financial Resilience with $41.7M Cash and Strategic R&D Investments
Corvus Pharmaceuticals Inc. (CRVS) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment landscape for cancer and…
Avidity Biosciences (RNA): Strengthened by $1.6 Billion Cash Position and Strategic Partnerships
Avidity Biosciences Inc. (RNA) is a pioneering biopharmaceutical company revolutionizing the field of RNA therapeutics. Through its proprietary…
The Future of Genomics: GeneDx (WGS) Achieves Profitability & Expands Market Reach
GeneDx Holdings Corp. (WGS) is a pioneering leader in the genomic diagnostics industry, dedicated to transforming healthcare through…
Hoth Therapeutics Inc. (HOTH): Investing in Life-Changing Therapies
Hoth Therapeutics Inc. (HOTH) is a clinical-stage biopharmaceutical company revolutionizing treatments for unmet medical needs across diverse therapeutic…
Pacific Biosciences (PACB): A Pioneer in Genomics Innovation and Growth Potential
Pacific Biosciences of California Inc. (PACB) remains a prominent player in the rapidly evolving genomics industry, known for…
Novavax (NVAX): A Game-Changer in Biotechnology and a Smart Investment Choice
Novavax Inc. (NVAX) is a pioneering biotechnology company specializing in innovative vaccine development using its proprietary protein-based platform.…
Longboard (LBPH): The Future of Neurological Disease Treatment
Longboard Pharmaceuticals Inc. (LBPH), a clinical-stage biopharmaceutical company, is redefining the treatment landscape for neurological disorders. With an…